Global Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), by Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,431.89 Million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increased adoption of strategies such as collaborations by key players in market to promote hereditary angioedema drugs in various regions is expected to drive market growth over the forecast period. For instance, on June 9, 2022, BioCryst Pharmaceuticals, Inc., a company that designs and develops small molecule medicines for rare diseases such as hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), announced that the company had entered into an exclusive collaboration with Pint Pharma GmbH, an Austria-based pharmaceutical company, to register and promote ORLADEYO (berotralstat) in the pan-Latin America (LATAM) region.
Global Hereditary Angioedema Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.
The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. Similarly, the COVID-19 pandemic had a negative impact on the overall growth of the hereditary angioedema market, owing to movement restrictions and lockdowns.
Global Hereditary Angioedema Market: Key Developments
In April 2022, Takeda Pharmaceutical Company Limited., a research-based global company, announced that TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe was available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older
On June 6, 2022, BioCryst Pharmaceuticals, Inc., a company that designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), announced that Health Canada had approved oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
Browse 58 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Global Hereditary Angioedema Market”- Forecast to 2030, Global Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), by Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the hereditary angioedema market, click the link below:
https://www.coherentmarketinsights.com/market-insight/hereditary-angioedema-market-1292
Moreover, increasing research and development activities by researchers to develop hereditary angioedema drugs is expected to drive market growth over the forecast period. For instance, in November 2021, Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program. Donidalorsen is an investigational antisense medicine designed to reduce the production of prekallikrein, which plays a key role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE).
Key Takeaways of the Global Hereditary Angioedema Market:
- Global hereditary angioedema market is expected to exhibit a CAGR of 9.1% during the forecast period due to increasing launches of hereditary angioedema drugs. For instance, in September 2021, Cycle Pharmaceuticals, a global, privately-owned and patient-dedicated biotechnology company, announced the launch of SAJAZIR (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE)
- Among distribution channels, the hospital pharmacies segment is expected to dominate the segment over the forecast period, due to need of healthcare resource utilization or hospital admissions. For instance, according to an article published by National Center for Biotechnology Information, in October 2018, sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the healthcare resource utilization (HCRU) analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED). Eighteen patients (5.4%) had a central venous access device (CVAD); of these, 5 (27.7%) required hospitalization and 14 (77.7%) had an ED visit.
- On the basis of regions, North America is estimated to account for the largest market share in the global hereditary angioedema market over the forecast period, owing to increasing product launches for hereditary angioedema in the region. For instance, in January 2021, Sandoz, a global company specialized in generic pharmaceuticals and biosimilars, announced the US launch of generic Icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema (HAE) in adults 18 years and older
- Major players operating in the global hereditary angioedema market include CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi
